<DOC>
	<DOCNO>NCT00000782</DOCNO>
	<brief_summary>To determine frequency delayed-type hypersensitivity ( DTH ) reaction HIV-positive patient two dos two envelope glycoprotein antigen prepare differently . To determine whether patient previously demonstrate DTH response intradermal MGStage HIV-1 gp160 IIIB baculovirus ( MicroGeneSys ) reproducible response repeat injection gp160 whether cross-reactivity intradermal HIV-1 rgp160 IIIB vero cell express ( Immuno-AG ) . PER 4/5/95 AMENDMENT : To also determine whether patient respond HIV-1 rgp160 IIIB baculovirus ( MicroGeneSys ) cross-reactivity intradermal skin test HIV-1 rgp160 MN ( Immuno-AG ) . Previous study individual immunize gp160 suggest skin test response immunize patient use surrogate marker new proliferative cytotoxic response induced vaccination .</brief_summary>
	<brief_title>A Phase I/II Study Delayed-Type Hypersensitivity ( DTH ) Reactions Intradermal HIV Envelope Antigen</brief_title>
	<detailed_description>Previous study individual immunize gp160 suggest skin test response immunize patient use surrogate marker new proliferative cytotoxic response induced vaccination . Patients stratify three group . Fifteen patient previously immunize MicroGeneSys rgp160 antigen ACTG 137 antiretroviral therapy receive intradermal injection Immuno-AG rgp160 IIIB ( vero cell express ) one arm , follow 1 week later intradermal injection MicroGeneSys rgp160 IIIB ( baculovirus express ) opposite arm ( stratum 1 ) . Forty patient previously immunize rgp160 receive intradermal injection Immuno-AG gp160 IIIB one arm simultaneously MicroGeneSys gp160 IIIB opposite arm ; patient either antiretroviral therapy ( stratum 2 ) currently antiretroviral therapy ( stratum 3 ) . All patient return 48 hour injection skin test reading . PER 4/5/95 AMENDMENT : Patients strata re-enroll receive Immuno-AG rgp160 MN one arm simultaneously MicroGeneSys rgp160 IIIB opposite arm .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Delayed</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed Step 2 ( PER 4/5/95 AMENDMENT ) : Approved antiretroviral drug . Patients must : Documented HIV infection . CD4 count &gt; = 400 cells/mm3 . NO current active opportunistic infection neoplasm ( stable cutaneous Kaposi 's sarcoma ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity insect protein . Concurrent Medication : Excluded : Antihistamine antiinflammatory medication 48hour period injection skin test reading . Topical steroid . Prior Medication : PER 4/5/95 AMENDMENT Excluded : Prior immunization experimental HIV vaccine ( strata 2 3 ) . Systemic corticosteroid , topical corticosteroid arm , systemic immunosuppressant agent antineoplastic agent within 30 day prior study entry . Antihistamine antiinflammatory medication within 72 hour prior intradermal injection . PREVIOUS VERSION Excluded within 30 day prior study entry : Any antiretroviral drug ( AZT , ddI , ddC , d4T patient stratum 3 ) . Systemic corticosteroid , topical corticosteroid arm , systemic immunosuppressant agent antineoplastic agent . Excluded within 72 hour prior intradermal injection : Antihistamine antiinflammatory medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Injections , Intradermal</keyword>
	<keyword>HIV Antigens</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Hypersensitivity , Delayed</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>